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STUDY ENDPOINTS
Primary Endpoint
• Investigator-assessed progression-free survival by 
Response Evaluation Criteria In Solid Tumors version 1.1 
(RECIST)10
Secondary Endpoints
• Overall survival
• Objective response rate by RECIST and by RECIST/cancer 
antigen 125 (CA-125) criteria
• Duration of response
• Patient-reported outcomes by European Organisation for 
Research and Treatment of Cancer Quality-of-Life 
Questionnaire (QLQ-C30) and the ovarian cancer module 
(QLQ-OV28)11,12
• Safety and tolerability of rucaparib vs SOC chemotherapy
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ARIEL4: An International, Multicenter, Randomized 
Phase 3 Study of the PARP Inhibitor Rucaparib vs 
Chemotherapy in Germline or Somatic BRCA1-
or BRCA2-Mutated, Relapsed, High-Grade 
Ovarian Carcinoma
INTRODUCTION
• In high-grade ovarian cancer, including fallopian tube and primary 
peritoneal cancers, approximately 18% of patients have tumors 
with a germline BRCA1 or BRCA2 mutation and approximately 7% 
of patients have tumors with a somatic BRCA1 or BRCA2 mutation1
• The poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib has 
demonstrated efficacy in tumors with homologous recombination 
deficiency (HRD), including a BRCA1 or BRCA2 mutation2-5
– In cells with HRD, PARP inhibition results in accumulation of 
double-strand DNA breaks that cannot be repaired, leading to 
cell death6-8
• Based on data from 2 single-arm clinical trials,4-5 rucaparib has 
received accelerated approval in the United States as 
monotherapy for the treatment of patients with deleterious BRCA
mutation (germline and/or somatic) associated advanced ovarian 
cancer who have been treated with ≥2 chemotherapies
• Although PARP inhibitors have demonstrated clinical activity in 
high-grade ovarian cancer in both treatment and maintenance 
settings, data comparing PARP inhibitors to standard of care 
(SOC) treatment for relapsed ovarian cancer are limited9
• Randomized studies in patients with BRCA1- or BRCA2-mutated, 
relapsed, high-grade ovarian cancer are needed to assess the 
benefit-risk profile of PARP inhibitors vs current SOC for this patient 
population, particularly in the third-line or later treatment setting
*Patients with a known BRCA mutation based on local test result must also submit tumor tissue; however, enrollment is not contingent on this tumor analysis.
†Progressed ≥1 to <6 months after last dose of platinum.
‡Progressed ≥6 to <12 months after last dose of platinum.
§Paclitaxel 60 to 80 mg/m2 on days 1, 8, and 15; administered per local standard of care and regulations.
ǁProgressed ≥12 months after last dose of platinum.
¶Cisplatin or carboplatin; administered per local standard of care and regulations.
#Carboplatin/paclitaxel, carboplatin/gemcitabine, or cisplatin/gemcitabine; administered per local standard of care and regulations.
BID, twice daily; HRD, homologous recombination deficiency; PARP, poly(ADP-ribose) polymerase; RECIST, Response Evaluation Criteria In Solid Tumors version 1.1.
PATIENT ELIGIBILITY
Table 1. Key Patient Inclusion/Exclusion Criteria
ARIEL4 TRIAL OVERVIEW
• ARIEL4 (CO-338-043; NCT02855944) is an international, 
multicenter, randomized phase 3 study evaluating rucaparib 
600 mg twice daily vs SOC chemotherapy as treatment for 
patients with germline or somatic BRCA1- or BRCA2-mutated, 
relapsed, high-grade ovarian cancer (platinum sensitive or 
resistant) who have received ≥2 prior chemotherapy regimens 
(Figure 1)
TRIAL SUMMARY
• Rucaparib has demonstrated efficacy in the treatment 
setting in patients with ovarian cancer and a deleterious 
BRCA1 or BRCA2 mutation4,5,13
• The ARIEL4 phase 3 study aims to assess the benefit-risk 
profile of rucaparib vs current SOC chemotherapy as 
treatment for patients with BRCA1- or BRCA2-mutated, 
relapsed, high-grade ovarian cancer
• ARIEL4 is actively recruiting patients, with a goal of 
enrolling 345 patients from >100 sites worldwide (Figure 2)
Figure 2. Countries Participating in ARIEL4
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Key inclusion criteria
• ≥18 years of age 
• Histologically or cytologically confirmed high-grade serous or grade 2 or 
grade 3 endometrioid epithelial ovarian, fallopian tube, or primary 
peritoneal cancera
• Received ≥2 prior chemotherapy regimens and currently has relapsed or 
progressive disease as confirmed by radiologic assessment
– Had treatment-free interval of ≥6 months following the first
chemotherapy regimen received
• Evaluable disease, ie, ≥1 target or nontarget lesion that can be assessed 
per RECIST
• Deleterious BRCA1 or BRCA2 mutation by local testing or central 
laboratory HRD testb
– Adequate screening and/or archival (formalin-fixed, paraffin-
embedded) tissue available for analysis
• Adequate organ function
Key exclusion criteria
• Prior PARP inhibitor treatment or treatment with single-agent paclitaxel 
for platinum-resistant disease
• Prior known hypersensitivity to paclitaxel (patients with PFI <12 months) 
or hypersensitivity to platinum (patients with PFI ≥12 months)
• Platinum-refractory disease (ie, disease progression during or within 
4 weeks of completion of most recent platinum-based therapy)
• Symptomatic and/or untreated CNS metastases
• Active secondary malignancy for which patient may be (but not 
necessarily) currently receiving treatment
• Ongoing grade ≥2 adverse event, with exception of peripheral 
neuropathy, which may be permitted with prior advanced approval
aPatients with a histology other than serous or endometrioid are also eligible if they are known to harbor a 
deleterious germline or somatic BRCA1 or BRCA2 mutation.
bPatients with a known deleterious BRCA1 or BRCA2 mutation based on local assessment must also 
submit archival tumor tissue for central laboratory testing.
CNS, central nervous system; HRD, homologous recombination deficiency; PARP, poly(ADP-ribose) 
polymerase; PFI, progression-free interval; RECIST, Response Evaluation Criteria In Solid Tumors 
version 1.1.
Figure 1. ARIEL4 Trial Schema
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